Feasibility of AC/EC followed by weekly paclitaxel in node-positive breast cancer in Japan.
Anticancer Res
; 29(5): 1515-20, 2009 May.
Article
em En
| MEDLINE
| ID: mdl-19443359
ABSTRACT
UNLABELLED The feasibility and efficacy of adriamycin or epirubicin in combination with cyclophosphamide followed by weekly paclitaxel (AC/EC-weekly PAC) as adjuvant chemotherapy for breast cancer was investigated. PATIENTS AND METHODS:
Node-positive breast cancer was treated with AC/ EC-weekly PAC, namely AC at 60/600 mg/m(2) or EC at 90/600 mg/m(2) x4 at three-week intervals, followed by weekly PAC (80 mg/m(2)) x 12, namely four cycles of single weekly administration for three weeks followed by a one-week rest (3 x 4 PAC) or single weekly administration for 12 consecutive weeks (12 PAC).RESULTS:
One hundred and three of 109 consecutive patients enrolled were analyzed, of whom 96 (93.2%) completed the regimen. Grade 3/4 neutropenia occurred in 52.4% receiving AC/EC, and 10.9% of 55 receiving 12 PAC but only 2.1% of 48 receiving 3 x 4 PAC. Neuropathy disorders occurred in more than half receiving PAC, which did not improve after one-week rest in 3 x 4 PAC.CONCLUSION:
AC/EC-weekly PAC is feasible and without serious complications.
Buscar no Google
Base de dados:
MEDLINE
Assunto principal:
Neoplasias da Mama
/
Protocolos de Quimioterapia Combinada Antineoplásica
/
Metástase Linfática
Limite:
Adult
/
Aged
/
Female
/
Humans
/
Middle aged
País como assunto:
Asia
Idioma:
En
Ano de publicação:
2009
Tipo de documento:
Article